Home/Pipeline/Injectable HDV-Rapid Acting Insulin (Open Label, MoA)

Injectable HDV-Rapid Acting Insulin (Open Label, MoA)

Diabetes

Phase 2Active

Key Facts

Indication

Diabetes

Phase

Phase 2

Status

Active

Company

Diasome Pharmaceuticals

About Diasome Pharmaceuticals

Diasome Pharmaceuticals is a clinical-stage biotech leveraging its HDV™ platform to create liver-targeted therapies for metabolic diseases. Its core technology uses a lipid nanoparticle (bicelle) with a biotin tag to selectively deliver drug actives to hepatocytes, aiming to enhance efficacy and reduce side effects by restoring natural physiological pathways. The most advanced program, OPTI-2 (HDV-Rapid Acting Insulin), is in Phase 2b for Type 1 Diabetes, with preclinical programs in GLP-1 and serotonin-based therapies. As a private company, Diasome is positioned to address significant unmet needs in the large and growing diabetes and obesity markets.

View full company profile

Therapeutic Areas

Diabetes Obesity Metabolic Diseases

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
Oral Insulin	Premas Biotech	Phase 3	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Glucose-Responsive Insulin Receptor Agonist	Protomer Technologies	Pre-clinical (integrated into Lilly pipeline)	Active